Eficacia del uso de antipsicóticos para el tratamiento de la irritabilidad y la psicosis en pacientes de 2 a 17 años con trastorno del espectro autista: Revisión sistemática
| dc.contributor.advisor | Toledo, Daniel | |
| dc.contributor.author | Oviedo Gomez, Leisly Tatiana | |
| dc.contributor.orcid | Oviedo Gomez, Leisly Tatiana [0009-0006-5775-3734] | |
| dc.date.accessioned | 2024-12-11T20:34:25Z | |
| dc.date.available | 2024-12-11T20:34:25Z | |
| dc.date.issued | 2024-08 | |
| dc.description.abstract | El trastorno del espectro autista (TEA) es una patología del neurodesarrollo que se caracteriza por presentar 1) un deterioro en la interacción social (2) deterioro en la comunicación y (3) patrones restringidos, repetitivos y estereotipados de comportamiento, actividades o intereses.; y puede estar asociada o no ha alteraciones del lenguaje o discapacidad intelectual. Además, el TEA puede asociarse con diversas conductas desafiantes, aproximadamente una cuarta parte de los pacientes con este diagnóstico tiene síntomas de irritabilidad que se puede expresar como rabietas, episodios de agresión hacia otros o hacia si mismo, y alteraciones rápidas del ánimo). Por otra parte un número más pequeño de pacientes (<1%) con TEA puede presentar síntomas psicóticos o un trastorno esquizofreniforme (TEE) dado por comportamiento desorganizado, ideas delirantes, alteraciones sensoperceptivas. Todas están conductas se convierten en factores claves para complicar la calidad de vida de estos pacientes al considerarse comportamientos desadaptativos que puede involucrar y agotar al cuidador principal del paciente y generar mayores complicaciones en el cuidado y manejo de esta condición médica. Existe pocos tratamientos antipsicóticos aprobados por la FDA para el tratamiento de las alteraciones de la conducta como por ejemplo el Aripiprazol y la Risperidona, por lo tanto, es necesario identificar los agentes farmacológicos antipsicóticos necesarios, disponibles, seguros y mejor tolerados por los pacientes menores de edad con diagnóstico de TEA. Existe escasa información actualizada en los últimos años que evidencien el tratamiento más eficaz para las alteraciones del comportamiento y alteraciones sensoperceptivas en menores de edad con TEA. Buscando aclarar este vacío se realizó una Revisión sistemática, el autor busco e incluyo los ensayos clínicos aleatorizados, metaanálisis, revisión sistemática de los últimos 10 años en donde se evaluó la eficacia del uso de antipsicóticos en irritabilidad y síntomas psicóticos en paciente de 2 a 17 años con diagnóstico de trastorno del espectro autista en las bases de datos Medline-PubMed, Cochrane Library, Lilacs, EMBASE. Mesh: Después de la selección y la extracción de los datos se realizó en un único formato de Excel, y se analizaron los datos. | |
| dc.description.abstractenglish | Autism spectrum disorder (ASD) is a neurodevelopmental pathology characterized by 1) impairment in social interaction (2) impairment in communication and (3) restricted, repetitive and stereotyped patterns of behavior, activities or interests. ; and may or may not be associated with language disorders or intellectual disability. In addition, ASD can be associated with various challenging behaviors; approximately a quarter of patients with this diagnosis have symptoms of irritability that can be expressed as tantrums, episodes of aggression toward others or oneself, and rapid mood disturbances). On the other hand, a smaller number of patients (<1%) with ASD may present psychotic symptoms or a schizophreniform disorder (SSD) due to disorganized behavior, delusional ideas, and sensory-perceptive alterations. All of these behaviors become key factors to complicate the quality of life of these patients as they are considered maladaptive behaviors that can involve and exhaust the patient's main caregiver and generate greater complications in the care and management of this medical condition. There are few antipsychotic treatments approved by the FDA for the treatment of behavioral disorders such as Aripiprazole and Risperidone, therefore, it is necessary to identify the antipsychotic pharmacological agents necessary, available, safe and best tolerated by patients under the age of 10. age with ASD diagnosis. There is little updated information in recent years that shows the most effective treatment for behavioral alterations and sensory-perceptive alterations in minors with ASD. Seeking to clarify this gap, a systematic review was carried out, the author searched for and included randomized clinical trials, meta-analysis, systematic review of the last 10 years where the effectiveness of the use of antipsychotics on irritability and psychotic symptoms in patients between 2 and 17 years old with a diagnosis of autism spectrum disorder in the databases Medline-PubMed, Cochrane Library, Lilacs, EMBASE. Mesh: After selection and data extraction was done in a single Excel format, and the data was analyzed. | |
| dc.description.degreelevel | Especialización | spa |
| dc.description.degreename | Especialista en Psiquiatría Infantil y del Adolescente | spa |
| dc.format.mimetype | application/pdf | |
| dc.identifier.instname | instname:Universidad El Bosque | spa |
| dc.identifier.reponame | reponame:Repositorio Institucional Universidad El Bosque | spa |
| dc.identifier.repourl | repourl:https://repositorio.unbosque.edu.co | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12495/13682 | |
| dc.language.iso | es | |
| dc.publisher.faculty | Facultad de Medicina | spa |
| dc.publisher.grantor | Universidad El Bosque | spa |
| dc.publisher.program | Especialización en Psiquiatría Infantil y del Adolescente | spa |
| dc.relation.references | 1. Autismo [Internet]. [cited 2023 Sep 28]. Available from: https://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0016-38132005000200009 | |
| dc.relation.references | 2. Enríquez-Sánchez H, Ochoa-Madrigal MG, Enríquez-Sánchez H, Ochoa-Madrigal MG. Espectro de la esquizofrenia en niños y adolescentes. Revista de la Facultad de Medicina (México) [Internet]. 2019 Jul 25 [cited 2023 Oct 1];62(4):9–23. Available from: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0026-17422019000400009&lng=es&nrm=iso&tlng=es | |
| dc.relation.references | 3. Cochran DM, Dvir Y, Frazier JA. “Autism-plus” Spectrum Disorders: Intersection with Psychosis and the Schizophrenia Spectrum. Child Adolesc Psychiatr Clin N Am. 2013 Oct 1;22(4):609–27. | |
| dc.relation.references | 4. Base de Datos Clínicos de Atención Primaria-BDCAP. [cited 2023 Nov 16]; Available from: https://cpage.mpr.gob.es/ | |
| dc.relation.references | 5. Estay J, Ale D, Morales S, Alarcón C. Trastorno de Espectro Autista y Psicosis. 2018;(2):122–30. | |
| dc.relation.references | 6. Loebel A, Brams M, Goldman RS, Silva R, Hernandez D, Deng L, et al. Lurasidone for the Treatment of Irritability Associated with Autistic Disorder. J Autism Dev Disord [Internet]. 2016 Apr 1 [cited 2024 Jul 10];46(4):1153–63. Available from: https://pubmed.ncbi.nlm.nih.gov/26659550/ | |
| dc.relation.references | 7. AmericAn PsychiAtric AssociAtion [Internet]. Available from: www.appi.org | |
| dc.relation.references | 8. Alcalá GC, Ochoa Madrigal MG, Alcalá GC, Ochoa Madrigal MG. Trastorno del espectro autista (TEA). Revista de la Facultad de Medicina (México) [Internet]. 2022 Jan 10 [cited 2023 Sep 28];65(1):7–20. Available from: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0026-17422022000100007&lng=es&nrm=iso&tlng=es The Journal of Human Pharmacology and Drug Therapy [Internet]. 2019 Jun 1 [cited 2024 Jul 10];39(6):626–35. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/phar.2271 | |
| dc.relation.references | 9. Víctor Ruggieri, Claudia Arberas. Trastornos generalizados del desarrollo: Aspectos clínicos y genéticos. Scielo [Internet]. 2007 [cited 2023 Sep 28];67:6–1. Available from: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802007000700006 | |
| dc.relation.references | 10. Historia resumida del autismo (I) - Fundacion ConecTEA - Juntos en el Autismo [Internet]. [cited 2023 Oct 25]. Available from: https://www.fundacionconectea.org/2023/02/28/historia-resumida-del-autismo-i/ | |
| dc.relation.references | 11. Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine [Internet]. 2014 Jun 17 [cited 2023 Sep 28];32(29):3623–9. Available from: https://pubmed.ncbi.nlm.nih.gov/24814559/ | |
| dc.relation.references | 12. Hutsler JJ, Love T, Zhang H. Histological and magnetic resonance imaging assessment of cortical layering and thickness in autism spectrum disorders. Biol Psychiatry [Internet]. 2007 Feb 15 [cited 2023 Sep 28];61(4):449–57. Available from: https://pubmed.ncbi.nlm.nih.gov/16580643/ | |
| dc.relation.references | 13. Buxhoeveden DP, Semendeferi K, Buckwalter J, Schenker N, Switzer R, Courchesne E. Reduced minicolumns in the frontal cortex of patients with autism. Neuropathol Appl Neurobiol [Internet]. 2006 Oct [cited 2023 Sep 28];32(5):483–91. Available from: https://pubmed.ncbi.nlm.nih.gov/16972882/ | |
| dc.relation.references | 14. Schumann CM, Amaral DG. Stereological analysis of amygdala neuron number in autism. J Neurosci [Internet]. 2006 [cited 2023 Sep 28];26(29):7674–9. Available from: https://pubmed.ncbi.nlm.nih.gov/16855095/ | |
| dc.relation.references | 15. White Junod S, Historian F. Folic Acid Fortification: Fact and Folly [Internet]. Available from: www.fda.gov | |
| dc.relation.references | 16. Geschwind DH. Autism: Many Genes, Common Pathways? Cell [Internet]. 2008 Oct 10 [cited 2023 Sep 28];135(3):391. Available from: /pmc/articles/PMC2756410/ | |
| dc.relation.references | 17. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest [Internet]. 2015 Mar 2 [cited 2023 Sep 28];125(3):926–38. Available from: https://pubmed.ncbi.nlm.nih.gov/25689247/ | |
| dc.relation.references | 18. Just MA, Cherkassky VL, Keller TA, Kana RK, Minshew NJ. Functional and anatomical cortical underconnectivity in autism: evidence from an FMRI study of an executive function task and corpus callosum morphometry. Cereb Cortex [Internet]. 2007 Apr [cited 2023 Sep 28];17(4):951–61. Available from: https://pubmed.ncbi.nlm.nih.gov/16772313/ | |
| dc.relation.references | 19. Moreno-De-Luca A, Evans DW, Boomer KB, Hanson E, Bernier R, Goin-Kochel RP, et al. The role of parental cognitive, behavioral, and motor profiles in clinical variability in individuals with chromosome 16p11.2 deletions. JAMA Psychiatry [Internet]. 2015 Feb 1 [cited 2023 Sep 28];72(2):119–26. Available from: https://pubmed.ncbi.nlm.nih.gov/25493922/ | |
| dc.relation.references | 20. Werner E, Dawson G. Validation of the phenomenon of autistic regression using home videotapes. Arch Gen Psychiatry [Internet]. 2005 Aug [cited 2023 Sep 29];62(8):889–95. Available from: https://pubmed.ncbi.nlm.nih.gov/16061766/ | |
| dc.relation.references | 21. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci [Internet]. 2000 [cited 2023 Oct 1];250(6):274–85. Available from: https://pubmed.ncbi.nlm.nih.gov/11153962/ | |
| dc.relation.references | 22. Kumra S, Oberstar J V., Sikich L, Findling RL, McClellan JM, Vinogradov S, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull [Internet]. 2008 Jan [cited 2023 Oct 1];34(1):60–71. Available from: https://pubmed.ncbi.nlm.nih.gov/17923452/ | |
| dc.relation.references | 23. Elena R, Flores U, Del T, Sauer Vera R, Guitart RA. Evaluación y tratamiento de la esquizofrenia en niños y adolescentes: una revisión actualizada. Vol. 34, Artículo original Salud Mental. 2011. | |
| dc.relation.references | 24. WERRY JS, MCCLELLAN JM, CHARD L. Childhood and adolescent schizophrenic, bipolar, and schizoaffective disorders: a clinical and outcome study. J Am Acad Child Adolesc Psychiatry [Internet]. 1991 [cited 2023 Oct 1];30(3):457–65. Available from: https://pubmed.ncbi.nlm.nih.gov/2055884/ | |
| dc.relation.references | 25. Asarnow RF, Forsyth JK. Genetics of childhood-onset schizophrenia. Child Adolesc Psychiatr Clin N Am [Internet]. 2013 Oct [cited 2023 Oct 1];22(4):675–87. Available from: https://pubmed.ncbi.nlm.nih.gov/24012080/ | |
| dc.relation.references | 26. Peralta V, Cuesta MJ. Eugen Bleuler and the Schizophrenias: 100 Years After. Schizophr Bull [Internet]. 2011 Nov 1 [cited 2023 Oct 1];37(6):1118–20. Available from: https://dx.doi.org/10.1093/schbul/sbr126 | |
| dc.relation.references | 27. Volkmar FR, Cohen DJ. Comorbid association of autism and schizophrenia. Am J Psychiatry [Internet]. 1991 [cited 2023 Oct 1];148(12):1705–7. Available from: https://pubmed.ncbi.nlm.nih.gov/1957933/ | |
| dc.relation.references | 28. Wachtel LE, Schuldt S, Ghaziuddin N, Shorter E. The potential role of electroconvulsive therapy in the ‘Iron Triangle’ of pediatric catatonia, autism, and psychosis. Acta Psychiatr Scand [Internet]. 2013 Nov 1 [cited 2023 Oct 1];128(5):408–9. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/acps.12158 | |
| dc.relation.references | 29. Rutter M. Childhood schizophrenia reconsidered. J Autism Child Schizophr. 1972 Sep;2(3):315–37. | |
| dc.relation.references | 30. Carroll LS, Owen MJ. Genetic overlap between autism, schizophrenia and bipolar disorder. Genome Med [Internet]. 2009 Oct 30 [cited 2023 Oct 1];1(10):1–7. Available from: https://genomemedicine.biomedcentral.com/articles/10.1186/gm102 | |
| dc.relation.references | 31. Chisholm K, Lin A, Abu-Akel A, Wood SJ. The association between autism and schizophrenia spectrum disorders: A review of eight alternate models of co-occurrence. Neurosci Biobehav Rev. 2015 Aug 1;55:173–83. | |
| dc.relation.references | 32. Kanne SMMMO. Aggression in children and adolescents with ASD: Prevalence and risk factors. J Autism Dev Disord. 2011 Jul 20;41(7):926–37. | |
| dc.relation.references | 33. Allen D, Evans C, Hider A, Hawkins S, Peckett H, Morgan H. Offending behaviour in adults with Asperger syndrome. J Autism Dev Disord [Internet]. 2008 Apr [cited 2024 Jun 5];38(4):748–58. Available from: https://www.researchgate.net/publication/6034485_Offending_Behaviour_in_Adults_with_Asperger_Syndrome | |
| dc.relation.references | 34. Juvenile and young adult mentally disordered offenders: the role of child neuropsychiatric disorders. Journal of the American Academy of Psychiatry and the Law, 29, 420-426 | Request PDF [Internet]. [cited 2024 Jun 5]. Available from: https://www.researchgate.net/publication/11572046_Juvenile_and_young_adult_mentally_disordered_offenders_the_role_of_child_neuropsychiatric_disorders_Journal_of_the_American_Academy_of_Psychiatry_and_the_Law_29_420-426 | |
| dc.relation.references | 35. Busner J, Targum SD. The Clinical Global Impressions Scale: Applying a Research Tool in Clinical Practice. Psychiatry (Edgmont) [Internet]. 2007 Jul [cited 2024 Jul 11];4(7):28. Available from: /pmc/articles/PMC2880930/ | |
| dc.relation.references | 36. Uso de Clinical Global Impressions-Severity (CGI-S) para evaluar | Psiquiatria.com [Internet]. [cited 2024 Jul 11]. Available from: https://psiquiatria.com/depresion/uso-de-clinical-global-impressions-severity-cgi-s-para-evaluar-la-respuesta-al-tratamiento-antidepresivo-en-pacientes-con-depresion-resistente-al-tratamiento | |
| dc.relation.references | 37. Adriana López Chente Soto I, Gerardo Hernández Rodríguez H, Elena Navarro Calvillo M, Gómez Navarro F, Lizbeth Gómez Elías C, González Gollaz G, et al. Validación de la versión en español de la Aberrant Behavior Checklist-Community en pacientes autistas mexicanos. Revista Mexicana de Neurociencia. 2018 Apr 26;19(2):49–61. | |
| dc.relation.references | 38. Schizophrenia in Children [Internet]. [cited 2023 Oct 25]. Available from: https://www.stanfordchildrens.org/es/topic/default?id=schizophreniainchildren-90-P05691 | |
| dc.relation.references | 39. Estay J, Ale D, Morales S, Alarcón C. Trastorno de Espectro Autista y Psicosis. 2018. | |
| dc.relation.references | 40. Talero-Gutiérrez C, Rodríguez M, De La Rosa D, Morales G, Vélez-Van-Meerbeke A. Caracterización de niños y adolescentes con trastornos del espectro autista en una institución de Bogotá, Colombia. Neurología. 2012 Mar 1;27(2):90–6. | |
| dc.relation.references | 41. Curso virtual interdisciplinario a distancia. salud mental, psicología y psicopatología del niño, el adolescente y su familia. evolución histórica del concepto de psicosis infantil. Delimitación del concepto de Esquizofrenia Infantil. | |
| dc.relation.references | 42. Versión 5.1.0 [Internet]. Available from: www.cochrane-handbook.org. | |
| dc.relation.references | 43. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ [Internet]. 2021 Mar 29 [cited 2023 Oct 24];372. Available from: https://www.bmj.com/content/372/bmj.n160 | |
| dc.relation.references | 44. Ichikawa H, Mikami K, Okada T, Yamashita Y, Ishizaki Y, Tomoda A, et al. Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study. Child Psychiatry Hum Dev [Internet]. 2017 Oct 1 [cited 2024 Jul 10];48(5):796–806. Available from: https://pubmed.ncbi.nlm.nih.gov/28004215/ | |
| dc.relation.references | 45. Ichikawa H, Hiratani M, Yasuhara A, Tsujii N, Oshimo T, Ono H, et al. An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan. Psychiatry Clin Neurosci [Internet]. 2018 Feb 1 [cited 2024 Jul 11];72(2):84–94. Available from: https://pubmed.ncbi.nlm.nih.gov/28941259/ | |
| dc.relation.references | 46. Levine SZ, Kodesh A, Goldberg Y, Reichenberg A, Furukawa TA, Kolevzon A, et al. Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. Eur Psychiatry [Internet]. 2016 Feb 1 [cited 2024 Jul 10];32:16–20. Available from: https://pubmed.ncbi.nlm.nih.gov/26802979/ | |
| dc.relation.references | 47. Findling RL, Mankoski R, Timko K, Lears K, McCartney T, McQuade RD, et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry [Internet]. 2014 [cited 2024 Jul 11];75(1):22–30. Available from: https://pubmed.ncbi.nlm.nih.gov/24502859/ | |
| dc.relation.references | 48. Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev [Internet]. 2014 Apr [cited 2024 Jul 10];45(2):185–92. Available from: https://pubmed.ncbi.nlm.nih.gov/23801256/ | |
| dc.relation.references | 49. DeVane CL, Charles JM, Abramson RK, Williams JE, Carpenter LA, Raven S, et al. Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial. Pharmacotherapy | |
| dc.rights | Attribution 4.0 International | en |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.accessrights | http://purl.org/coar/access_right/c_abf2 | |
| dc.rights.local | Acceso abierto | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Autismo | |
| dc.subject | Iritabilidad | |
| dc.subject | Psicosis | |
| dc.subject | Tratamiento farmacológico | |
| dc.subject | Antipsicótico | |
| dc.subject.keywords | Autism | |
| dc.subject.keywords | Irritability | |
| dc.subject.keywords | Psychosis | |
| dc.subject.keywords | Pharmacological treatment | |
| dc.subject.keywords | Antipsychotic | |
| dc.subject.nlm | WS 350 | |
| dc.title | Eficacia del uso de antipsicóticos para el tratamiento de la irritabilidad y la psicosis en pacientes de 2 a 17 años con trastorno del espectro autista: Revisión sistemática | |
| dc.title.translated | Efficacy of antipsychotic use for the treatment of irritability and psychosis in patients aged 2 to 17 years with autism spectrum disorder: Systematic review | |
| dc.type.coar | https://purl.org/coar/resource_type/c_7a1f | |
| dc.type.coarversion | https://purl.org/coar/version/c_ab4af688f83e57aa | |
| dc.type.driver | info:eu-repo/semantics/bachelorThesis | |
| dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | |
| dc.type.local | Tesis/Trabajo de grado - Monografía - Especialización | spa |
Archivos
Bloque original
1 - 1 de 1
Bloque de licencias
1 - 3 de 3
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 1.95 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción:
No hay miniatura disponible
- Nombre:
- Carta de autorizacion.pdf
- Tamaño:
- 149.07 KB
- Formato:
- Adobe Portable Document Format
- Descripción:
No hay miniatura disponible
- Nombre:
- Anexo 1 Probatus.pdf
- Tamaño:
- 151.22 KB
- Formato:
- Adobe Portable Document Format
- Descripción: